<DOC>
	<DOCNO>NCT01232374</DOCNO>
	<brief_summary>Nimotuzumab humanize monoclonal antibody epidermal growth factor receptor ( EGFR ) . Clinical trial ongoing globally evaluate Nimotuzumab different indication . Nimotuzumab approve treat squamous cell carcinoma head neck ( SCCHN ) , glioma nasopharyngeal carcinoma different country . The clinical phase I study combination Nimotuzumab administer concurrently chemo-irradiation patient local advance esophageal squamous cell carcinoma ( LAFSCC ) show safety potential efficacy Nimotuzumab . The concurrent trial clinical phase II trial design assess efficacy combination Nimotuzumab administer concurrently chemo-radiotherapy patient LAFSCC , investigate side-effect toxicity .</brief_summary>
	<brief_title>Nimotuzumab Combination With Chemoradiation Local Advanced Esophageal Squamous Cell Carcinoma</brief_title>
	<detailed_description>The concurrent trial clinical phase II trial design assess efficacy combination Nimotuzumab administer concurrently chemo-radiotherapy patient LAFSCC , investigate side-effect toxicity .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Joined study voluntarily sign informed consent form ; Age 1875 Both gender Esophageal squamous cell carcinoma confirm pathology Local advance esophageal squamous cell carcinoma ( T2N0M0TxNxM1a , AJCC 2002 ) No radiotherapy , chemotherapy treatment prior enrollment PS ECOG 02 Life expectancy 3 month Target lesion measurable Hemoglobin（Hb）≥9 g/dL WBC≥3x109/L , Neutrophils ( ANC ) ≥1.5x109/L platelet count ( Pt ) ≥100x 109/L Hepatic function : ALAT ASAT &lt; 2.5 x ULN , TBIL &lt; 1.5 x ULN Renal function : creatinine &lt; 1.5 x ULN No immunodeficiency Use effective contraceptive adult prevent pregnancy . Complete esophageal obstruction Deep esophageal ulcer Esophageal perforation Haematemesis After surgery , exploratory thoracotomy , radiotherapy , chemotherapy , target therapy Esophageal stent tracheal stent place Other malignant tumor , except skin basal cell carcinoma , cervical carcinoma situ , survive evidence disease 3 year Participation interventional clinical trial within 30 day Pregnant breastfeed woman people birthperiod refused take contraceptive Drug addiction Alcoholism AIDS Uncontrolled seizure psychiatric disease , loss control behavior History serious allergic allergy Patients suitable participate trial accord researcher .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Nimotuzumab</keyword>
	<keyword>local advance esophageal squamous cell carcinoma</keyword>
	<keyword>chemo-irradiation</keyword>
</DOC>